Table 1 Baseline characteristics of PLWH with NTM infection

General information

 Total number of patients

379

 Male sex

355 (93.7%)

 Age [years], Median (IQR)

38.0 (30.0–50.0)

 Smoking (current or former)

28 (7.4%)

 Alcoholism

10 (2.6%)

 Comorbidity

113 (29.8%)

 Opportunistic infection

136 (35.9%)

   Cryptococcosis

35 (25.7%)

   Cytomegalovirus

28 (20.6%)

   Digestive tract fungal infections

23 (16.9%)

   Pneumocystis pneumonia

12 (8.8%)

   Talaromyces marneffei

11 (8.1%)

   Kaposi’s Sarcoma

8 (5.9%)

   Herpes zoster

5 (3.7%)

   Mycobacterium tuberculosis

4 (2.9%)

   Salmonella infection

3 (2.2%)

   Pulmonary aspergillosis

2 (1.5%)

   Bacterial pneumonia

2 (1.5%)

   Cerebral toxoplasmosis

2 (1.5%)

   Progressive multifocal leukoencephalopathy

1 (0.7%)

Clinical manifestations

 Fever

236 (63.4%)

 Cough

164 (44.1%)

 HIV wasting syndrome

81 (22.8%)

 Abdominal pain and diarrhea

68 (18.3%)

 Central nervous system symptoms

48 (12.9%)

 Rash

43 (11.6%)

HIV-related indicators

 CD4⁺ T cell count [cells/μl], Median (IQR)

23 (6.0–73.8)

 HIV viral load [log10 copies/ml], Median (IQR)

4.8 (1.9–5.5)

 ART before NTM treatment

294 (77.6%)

 ART to anti-NTM time, Median (IQR)

31 (4.0–127.0)

NTM treatment

 Macrolides

280 (73.9%)

 Levofloxacin/Moxifloxacin

248 (65.4%)

 Ethambutol

317 (83.6%)

 Rifampicin/Rifabutin

248 (65.4%)

 Linezolid

23 (6.1%)